argenx SE ARGX 深 沪
已收盘 10-02 16:00:00 美东时间
919.21
-16.790
-1.79%
华盛通- 最 高928.96
- 今 开926.86
- 成交量 33.39万股
- 最 低 912.96
- 昨 收 936.00
- 总市值 575.07亿
- 52周最高 1072.75
- 市盈率 静 46.83
- 换手率 0.53%
- 52周最低 661.85
- 委 比 95.83%
- 总股本 6256.10万
- 历史最高 1072.75
- 量 比 1.20
- 振 幅 1.71%
- 历史最低 19.00
- 每 手 1
- 风险率 79.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.58% on an annualized basis producing an average annual return of 24.86%. Currently, argenx has a market capitalization of $64.63 billion. Buying $100 In ARGX: If an investor had bought $100 of ARGX stock 5 years ago, it wou...
09-05 04:15
美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
Wedbush Reiterates Outperform on argenx, Maintains $1150 Price Target
Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintains $1150 price target.
09-03 21:17
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
美股大行评级 | 潜在涨幅1849.95%！Ascendiant Capital上调IGC Pharma目标价至6美元，维持"买入"评级；迪克体育、财捷遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.5美元升至6美元；Ascendiant Capital：维持Quantum Computing"买入"评级，目标价从30美元升至32美元
08-27 08:37
Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1415
Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1350 to $1415.
08-26 20:47
美股盘前 | 韩国电力大升5.51%，Summit Therapeutics上升4.79%
韩国电力大升5.51%；Summit Therapeutics上升4.79%；先科电子上升3.36%
08-26 16:11
These Analysts Boost Their Forecasts On Argenx
Argenx SE (NASDAQ:ARGX) on Monday disclosed positive topline results from its Phase 3 ALKIVIA study. The trial evaluated VYVGART Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with autoimmune myositis. The study successfully achieved its primary endpoint (p=0.0011). “For decades, pe...
08-18 20:12
美股牛股 | 英伟达挑战者CBRS劲升15%，为OpenAI新模型提供算力；铠侠ADR升逾13%
受磷化铟抢货潮利好！半导体材料股AXT飙升17%；ARGX劲升16%，治疗自身免疫性肌炎药物临床试验积极；英伟达挑战者CBRS升逾15%，为OpenAI新模型提供算力>>
08-18 17:03
